Compare PWP & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PWP | EYPT |
|---|---|---|
| Founded | 2006 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2020 | 2005 |
| Metric | PWP | EYPT |
|---|---|---|
| Price | $21.60 | $15.05 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $23.50 | ★ $31.80 |
| AVG Volume (30 Days) | 758.0K | ★ 813.4K |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.30% | N/A |
| EPS Growth | ★ 138.52 | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | N/A | ★ $7,539,000.00 |
| Revenue This Year | $31.87 | N/A |
| Revenue Next Year | $16.54 | $3,115.57 |
| P/E Ratio | $45.85 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.59 | $5.46 |
| 52 Week High | $25.93 | $19.11 |
| Indicator | PWP | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 73.99 | 59.39 |
| Support Level | $20.70 | $14.50 |
| Resistance Level | $23.01 | $18.99 |
| Average True Range (ATR) | 0.87 | 0.64 |
| MACD | 0.40 | 0.26 |
| Stochastic Oscillator | 78.79 | 91.22 |
Perella Weinberg Partners is an independent advisory firm that provides strategic and financial advice to a wide range of clients. The Company's activities as an investment banking advisory firm constitute a single business segment that provides a range of advisory services, including advice related to strategic and financial decisions, mergers and acquisitions execution, shareholder and defense advisory, financing and capital solutions advice with resources focused on restructuring and liability management, capital markets advisory, private capital placement, as well as specialized underwriting and research services for the energy and related industries.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.